Keryx Posts In-Line Loss in Q2, Auryxia in Focus
Keryx Biopharmaceuticals Inc. ’s KERX second-quarter 2015 loss of 26 cents per share was in line with the Zacks Consensus Estimate but wider than the year-ago figure of a loss of 24 cents. Keryx Biopharmaceuticals Inc. […]